Zobrazeno 1 - 10
of 583
pro vyhledávání: ''
Autor:
Minami Omura, Eiji Kikuchi, Keisuke Shigeta, Koichiro Ogihara, Kyohei Hakozaki, Satoshi Hara, Suguru Shirotake, Hiroki Ide, Shunsuke Yoshimine, Takashi Ohigashi, Ryuichi Mizuno, Mototsugu Oya
Publikováno v:
Japanese Journal of Clinical Oncology. 52:388-396
Background Although the administration of neoadjuvant chemotherapy has been associated with improved prognosis in patients with muscle-invasive bladder cancer, the therapeutic effects of adjuvant chemotherapy remain unknown in real-world settings. Th
Publikováno v:
Japanese Journal of Clinical Oncology
Background We aimed to evaluate cost-effectiveness of enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer patients in Japan. Methods A Markov model was developed to capture time spent by patients in various health stat
Autor:
Hajime Yonezawa, Yoshitaka Narita, Satoshi Shima, Yukie Tamura, Masamichi Takahashi, Yuko Matsushita, Hiroshi Igaki, Yasuji Miyakita, Koichi Ichimura, Makoto Ohno
Publikováno v:
Japanese Journal of Clinical Oncology. 51:1028-1035
Background There is no standard treatment for patients with recurrent high-grade gliomas who progress after bevacizumab treatment. We evaluated the outcomes of re-irradiation combined with bevacizumab for patients refractory to bevacizumab. Methods B
Publikováno v:
Japanese journal of clinical oncology. 52(11)
Background It remains unclear whether laparoscopic gastrectomy with optimal lymphadenectomy is appropriate for very elderly patients with advanced gastric cancer. This study aimed to assess the validity of laparoscopic gastrectomy with D1+ lymphadene
Publikováno v:
Japanese Journal of Clinical Oncology. 51:905-910
Objective The aim of the present study was to retrospectively evaluate the toxicity and efficacy of post-operative small pelvic intensity-modulated radiotherapy in early-stage cervical cancer patients with intermediate-risk factors. Methods Between 2
Autor:
Ava Kwong, Cuizhi Geng, Qingyuan Zhang, Donggeng Liu, Ning Liao, Wei Li, Zhimin Shao, Da Pang, Youngsen Yang, Ling-Ming Tseng, Chiun-Sheng Huang, Binghe Xu
Publikováno v:
Japanese Journal of Clinical Oncology. 51:345-353
Background The addition of pertuzumab to trastuzumab plus standard chemotherapy as adjuvant therapy following surgery significantly improved invasive disease-free survival (IDFS) in patients with HER2-positive early breast cancer in the multinational
Autor:
Zheyu Niu, Xie Song, Hengjun Gao, Xu Zhou, Yuanyuan Zong, Jun Lu, Faji Yang, Huaqiang Zhu, Zhen Yang
Publikováno v:
Japanese Journal of Clinical Oncology. 51:595-603
Objective There are limited data from retrospective studies on whether therapeutic outcomes after regular pancreatectomy are superior to those after enucleation in patients with small, peripheral and well-differentiated non-functional pancreatic neur
Publikováno v:
Japanese Journal of Clinical Oncology. 51:424-433
Objective To explore the immunohistochemistry-based molecular subtypes of bladder cancer, and their impact on the prognosis and the chemotherapy response between gemcitabine plus cisplatin intra-arterial chemotherapy and epirubicin-inducted intravesi
Autor:
H Kobayashi, M Iinuma, Hiroomi Nakatsu, Kazuo Mikami, Takefumi Satoh, A Maniwa, H Kikukawa, Naoto Kamiya, Koichi Kobayashi, Kenneth K. Tanabe, T Nakashima, N Okuno, Yasutomo Nasu, Hirotsugu Uemura, Gaku Arai, Junya Furukawa
Publikováno v:
Japanese Journal of Clinical Oncology
Aim The aim was to evaluate the efficacy and safety of abiraterone acetate plus prednisolone in patients with chemotherapy-naïve early metastatic castration-resistant prostate cancer who failed first-line androgen deprivation therapy. Methods Patien
Autor:
Hironori Fukuda, Kazuhiko Yoshida, Junpei Izuka, Toshio Takagi, Hiroki Ishihara, Hirohito Kobayashi, Kazunari Tanabe, Hidekazu Tachibana, Tsunenori Kondo
Publikováno v:
Japanese Journal of Clinical Oncology. 51:646-653
Purpose Combined immunotherapy of nivolumab plus ipilimumab for intermediate- and poor-risk metastatic clear cell renal cell carcinoma showed prolonged progression-free survival and high objective response rate in a randomized phase III clinical tria